An In-Depth Monograph on Lercanidipine (DB00528): Pharmacology, Clinical Efficacy, and Therapeutic Profile

Introduction and Drug Identification

Overview

Lercanidipine is a modern antihypertensive agent belonging to the dihydropyridine (DHP) class of calcium channel blockers (CCBs).[1] As a third-generation DHP, it represents a significant pharmacological advancement over earlier agents such as nifedipine and amlodipine, primarily distinguished by a more favorable tolerability profile.[3] The primary therapeutic function of Lercanidipine is to induce relaxation and vasodilation of peripheral arterioles, which allows blood to circulate more freely. This action effectively lowers systemic blood pressure and reduces the afterload against which the heart must pump, thereby improving cardiovascular efficiency.[1] Patented in 1984 and receiving its first medical approval in 1997, Lercanidipine has become a widely utilized treatment for hypertension in many countries, although it is not marketed in the United States.[1]

Chemical and Physical Properties

Lercanidipine is a small molecule drug identified by the Chemical Abstracts Service (CAS) number 100427-26-7 for the free base and 132866-11-6 for its commonly used hydrochloride salt.[1] Its chemical structure is complex, reflecting its specific pharmacological design. The molecular properties are summarized in Table 1.1.

Table 1.1: Key Chemical and Physical Identifiers for Lercanidipine